S
Sadahisa Ogasawara
Researcher at Chiba University
Publications - 145
Citations - 7127
Sadahisa Ogasawara is an academic researcher from Chiba University. The author has contributed to research in topics: Hepatocellular carcinoma & Medicine. The author has an hindex of 24, co-authored 104 publications receiving 4404 citations.
Papers
More filters
Journal ArticleDOI
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Andrew X. Zhu,Richard S. Finn,Julien Edeline,Stéphane Cattan,Sadahisa Ogasawara,Daniel H. Palmer,Chris Verslype,Vittorina Zagonel,Laetitia Fartoux,Arndt Vogel,Debashis Sarker,Gontran Verset,Stephen L. Chan,Jennifer J. Knox,Bruno Daniele,Andrea L. Webber,Scot Ebbinghaus,Junshui Ma,Abby B. Siegel,Ann-Lii Cheng,Masatoshi Kudo,Angela Tatiana Alistar,Jamil Asselah,Jean-Frédéric Blanc,Ivan Borbath,Timothy Cannon,Ki Chung,Allen Lee Cohn,David Cosgrove,Nevena Damjanov,Mukul Gupta,Yoshivasu Karino,Mark Karwal,Andreas Kaubisch,Robin Kate Kelley,Jena-Luc Van Laethem,Timothy Larson,James Lee,Daneng Li,Atisha Manhas,Gulam Abbas Manji,Kazushi Numata,Benjamin M. Parsons,Andrew Scott Paulson,Carmine Pinto,Robert A. Ramirez,Suresh Ratnam,Magnus Rizell,Olivier Rosmorduc,Yvonne Sada,Yutaka Sasaki,Per I Stal,Simone I. Strasser,Joerg Trojan,Gina M. Vaccaro,Hans Van Vlierberghe,Alan Weiss,Karl-Heinz Weiss,Tatsuya Yamashita +58 more
TL;DR: Pembrolizumab was effective and tolerable in patients with advanced hepatocellular carcinoma who had previously been treated with sorafenib and is undergoing further assessment in two phase 3, randomised trials as a second-line treatment.
Journal ArticleDOI
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
Masao Omata,Ann-Lii Cheng,Norihiro Kokudo,Masatoshi Kudo,Jeong Min Lee,Jidong Jia,Ryosuke Tateishi,Kwang Hyub Han,Yoghesh K. Chawla,Shuichiro Shiina,Wasim Jafri,Diana A. Payawal,Takamasa Ohki,Sadahisa Ogasawara,Pei-Jer Chen,Cosmas Rinaldi Adithya Lesmana,Laurentius A. Lesmana,Rino Alvani Gani,Shuntaro Obi,A. Kadir Dokmeci,Shiv Kumar Sarin +20 more
TL;DR: The latest guidelines for the treatment of HCC recommend evidence-based management and are considered suitable for universal use in the Asia–Pacific region, which has a diversity of medical environments.
Journal ArticleDOI
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn,Baek-Yeol Ryoo,Philippe Merle,Masatoshi Kudo,Mohamed Bouattour,Ho Yeong Lim,Valeriy Breder,Julien Edeline,Yee Chao,Sadahisa Ogasawara,Thomas Yau,Marcelo Garrido,Stephen L. Chan,Jennifer J. Knox,Bruno Daniele,Scot Ebbinghaus,Erluo Chen,Abby B. Siegel,Andrew X. Zhu,Ann-Lii Cheng +19 more
TL;DR: The results are consistent with those of KEYNOTE-224, supporting a favorable risk-to-benefit ratio for pembrolizumab in this population, and one-sided significance thresholds for OS and PFS did not reach statistical significance per specified criteria.
Journal ArticleDOI
JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan
Masatoshi Kudo,Osamu Matsui,Namiki Izumi,Hiroko Iijima,Masumi Kadoya,Yasuharu Imai,Takuji Okusaka,Shiro Miyayama,Kaoru Tsuchiya,Kazuomi Ueshima,Atsushi Hiraoka,Masafumi Ikeda,Sadahisa Ogasawara,Tatsuya Yamashita,Tetsuya Minami,Koichiro Yamakado +15 more
TL;DR: The Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma proposed by the Japan Society of Hepatology was updated in June 2014 at a consensus meeting of the Liver Cancer Study Group of Japan.
Journal ArticleDOI
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.
Masatoshi Kudo,Yusuke Kawamura,Kiyoshi Hasegawa,Ryosuke Tateishi,Kazuya Kariyama,Shuichiro Shiina,Hidenori Toyoda,Yasuharu Imai,Atsushi Hiraoka,Masafumi Ikeda,Namiki Izumi,Michihisa Moriguchi,Sadahisa Ogasawara,Yasunori Minami,Kazuomi Ueshima,Takamichi Murakami,Shiro Miyayama,Osamu Nakashima,Hirohisa Yano,Michiie Sakamoto,Etsuro Hatano,Mitsuo Shimada,Norihiro Kokudo,Satoshi Mochida,Tetsuo Takehara +24 more
TL;DR: The Clinical Practice Manual for Hepatocellular Carcinoma (HCC) as mentioned in this paper was published by the Japan Society of Hepatology (JSH) expert panel in 2007, with emphasis on the consensus statements and recommendations for the management of HCC.